NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.11
+0.35 (2.98%)
At close: Dec 5, 2025, 4:00 PM EST
12.08
-0.03 (-0.25%)
After-hours: Dec 5, 2025, 7:35 PM EST
NovoCure Revenue
NovoCure had revenue of $167.20M in the quarter ending September 30, 2025, with 7.81% growth. This brings the company's revenue in the last twelve months to $642.27M, up 11.17% year-over-year. In the year 2024, NovoCure had annual revenue of $605.22M with 18.82% growth.
Revenue (ttm)
$642.27M
Revenue Growth
+11.17%
P/S Ratio
2.08
Revenue / Employee
$431,632
Employees
1,488
Market Cap
1.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 605.22M | 95.88M | 18.82% |
| Dec 31, 2023 | 509.34M | -28.50M | -5.30% |
| Dec 31, 2022 | 537.84M | 2.81M | 0.53% |
| Dec 31, 2021 | 535.03M | 40.66M | 8.23% |
| Dec 31, 2020 | 494.37M | 143.05M | 40.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NVCR News
- 5 days ago - Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Business Wire
- 10 days ago - Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference - Business Wire
- 24 days ago - 2 Healthcare Stocks for Individual Investors With a 40-Year Time Horizon - The Motley Fool
- 24 days ago - Novocure to Participate in 2025 Jefferies Global Healthcare Conference - Business Wire
- 5 weeks ago - NovoCure Limited (NVCR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Novocure Reports Third Quarter 2025 Financial Results - Business Wire
- 7 weeks ago - NovoCure: Buy Rating As Pipeline Gains Drive Renewed Momentum - Seeking Alpha
- 7 weeks ago - Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress - Business Wire